Pfizer Goodwill and Intangible Assets 1986-2025 | PFE
Pfizer goodwill and intangible assets from 1986 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
- Pfizer goodwill and intangible assets for the quarter ending June 30, 2025 were $121.699B, a 6.16% decline year-over-year.
- Pfizer goodwill and intangible assets for 2024 were $123.938B, a 6.59% decline from 2023.
- Pfizer goodwill and intangible assets for 2023 were $132.683B, a 40.04% increase from 2022.
- Pfizer goodwill and intangible assets for 2022 were $94.745B, a 27.42% increase from 2021.
Pfizer Annual Goodwill and Intangible Assets
(Millions of US $) |
| 2024 |
$123,938 |
| 2023 |
$132,683 |
| 2022 |
$94,745 |
| 2021 |
$74,354 |
| 2020 |
$77,893 |
| 2019 |
$82,138 |
| 2018 |
$88,622 |
| 2017 |
$104,693 |
| 2016 |
$107,097 |
| 2015 |
$88,598 |
| 2014 |
$77,235 |
| 2013 |
$81,904 |
| 2012 |
$88,807 |
| 2011 |
$95,753 |
| 2010 |
$101,483 |
| 2009 |
$110,391 |
| 2008 |
$39,185 |
| 2007 |
$41,880 |
| 2006 |
$45,226 |
| 2005 |
$47,229 |
| 2004 |
$57,007 |
| 2003 |
$57,856 |
| 2002 |
$2,121 |
| 2001 |
$1,689 |
| 2000 |
$1,791 |
| 1999 |
$763 |
| 1998 |
$813 |
| 1997 |
$1,294 |
| 1996 |
$1,424 |
| 1995 |
$1,243 |
| 1994 |
$326 |
| 1993 |
$231 |
| 1992 |
$368 |
| 1991 |
$384 |
| 1990 |
$499 |
| 1989 |
$430 |
| 1988 |
$419 |
| 1987 |
$238 |
| 1986 |
$217 |
| 1985 |
$121 |
Pfizer Quarterly Goodwill and Intangible Assets
(Millions of US $) |
| 2025-06-30 |
$121,699 |
| 2025-03-31 |
$122,420 |
| 2024-12-31 |
$123,938 |
| 2024-09-30 |
$128,556 |
| 2024-06-30 |
$129,685 |
| 2024-03-31 |
$132,126 |
| 2023-12-31 |
$132,683 |
| 2023-09-30 |
$91,751 |
| 2023-06-30 |
$92,978 |
| 2023-03-31 |
$93,478 |
| 2022-12-31 |
$94,745 |
| 2022-09-30 |
$77,592 |
| 2022-06-30 |
$78,956 |
| 2022-03-31 |
$80,027 |
| 2021-12-31 |
$74,354 |
| 2021-09-30 |
$75,795 |
| 2021-06-30 |
$77,190 |
| 2021-03-31 |
$77,765 |
| 2020-12-31 |
$77,893 |
| 2020-09-30 |
$90,829 |
| 2020-06-30 |
$91,990 |
| 2020-03-31 |
$92,966 |
| 2019-12-31 |
$82,138 |
| 2019-09-30 |
$97,660 |
| 2019-06-30 |
$86,376 |
| 2019-03-31 |
$87,526 |
| 2018-12-31 |
$88,622 |
| 2018-09-30 |
$100,920 |
| 2018-06-30 |
$102,420 |
| 2018-03-31 |
$104,083 |
| 2017-12-31 |
$104,693 |
| 2017-09-30 |
$105,799 |
| 2017-06-30 |
$106,362 |
| 2017-03-31 |
$107,083 |
| 2016-12-31 |
$107,097 |
| 2016-09-30 |
$110,519 |
| 2016-06-30 |
$93,656 |
| 2016-03-31 |
$88,160 |
| 2015-12-31 |
$88,598 |
| 2015-09-30 |
$90,514 |
| 2015-06-30 |
$74,995 |
| 2015-03-31 |
$76,188 |
| 2014-12-31 |
$77,235 |
| 2014-09-30 |
$79,098 |
| 2014-06-30 |
$80,021 |
| 2014-03-31 |
$80,589 |
| 2013-12-31 |
$81,904 |
| 2013-09-30 |
$82,949 |
| 2013-06-30 |
$84,207 |
| 2013-03-31 |
$87,861 |
| 2012-12-31 |
$88,807 |
| 2012-09-30 |
$91,579 |
| 2012-06-30 |
$92,967 |
| 2012-03-31 |
$98,053 |
| 2011-12-31 |
$95,753 |
| 2011-09-30 |
$101,006 |
| 2011-06-30 |
$102,166 |
| 2011-03-31 |
$103,350 |
| 2010-12-31 |
$101,483 |
| 2010-09-30 |
$102,414 |
| 2010-06-30 |
$105,373 |
| 2010-03-31 |
$107,128 |
| 2009-12-31 |
$110,391 |
| 2009-09-30 |
$37,921 |
| 2009-06-30 |
$38,405 |
| 2009-03-31 |
$38,405 |
| 2008-12-31 |
$39,185 |
| 2008-09-30 |
$40,331 |
| 2008-06-30 |
$41,579 |
| 2008-03-31 |
$41,452 |
| 2007-12-31 |
$41,880 |
| 2007-09-30 |
$42,208 |
| 2007-06-30 |
$43,887 |
| 2007-03-31 |
$44,412 |
| 2006-12-31 |
$45,226 |
| 2006-09-30 |
$46,374 |
| 2006-06-30 |
$47,191 |
| 2006-03-31 |
$51,814 |
| 2005-12-31 |
$47,229 |
| 2005-09-30 |
$52,782 |
| 2005-06-30 |
$53,409 |
| 2005-03-31 |
$54,672 |
| 2004-12-31 |
$57,007 |
| 2004-09-30 |
$56,676 |
| 2004-06-30 |
$57,289 |
| 2004-03-31 |
$59,454 |
| 2003-12-31 |
$57,856 |
| 2003-09-30 |
$57,151 |
| 2003-06-30 |
$59,537 |
| 2003-03-31 |
$1,230 |
| 2002-12-31 |
$2,121 |
| 2002-09-30 |
$1,304 |
| 2002-06-30 |
$1,288 |
| 2002-03-31 |
$1,824 |
| 2001-12-31 |
$1,689 |
| 2001-09-30 |
$1,764 |
| 2001-06-30 |
$1,776 |
| 2001-03-31 |
$1,797 |
| 2000-12-31 |
$1,791 |
| 2000-09-30 |
$1,761 |
| 2000-06-30 |
$1,806 |
| 2000-03-31 |
$753 |
| 1999-12-31 |
$763 |
| 1999-09-30 |
$776 |
| 1999-06-30 |
$779 |
| 1999-03-31 |
$788 |
| 1998-12-31 |
$813 |
| 1998-09-30 |
$883 |
| 1998-06-30 |
$1,023 |
| 1998-03-31 |
$1,270 |
| 1997-12-31 |
$1,294 |
| 1997-09-30 |
$1,316 |
| 1997-06-30 |
$1,344 |
| 1997-03-31 |
$1,375 |
| 1996-12-31 |
$1,424 |
| 1996-09-30 |
$1,478 |
| 1996-06-30 |
$1,476 |
| 1996-03-31 |
$1,327 |
| 1995-12-31 |
$1,243 |
| 1995-09-30 |
$1,174 |
| 1995-06-30 |
$1,218 |
| 1995-03-31 |
$1,212 |
| 1994-12-31 |
$326 |
| 1994-09-30 |
$292 |
| 1994-06-30 |
$289 |
| 1994-03-31 |
$261 |
| 1993-12-31 |
$231 |
| 1993-09-30 |
$234 |
| 1993-06-30 |
$363 |
| 1993-03-31 |
$358 |
| 1992-12-31 |
$368 |
| 1992-09-30 |
$362 |
| 1992-06-30 |
$345 |
| 1992-03-31 |
$364 |
| 1991-12-31 |
$384 |
| 1991-09-30 |
$479 |
| 1991-06-30 |
$483 |
| 1991-03-31 |
$497 |
| 1990-12-31 |
$499 |
| 1990-09-30 |
$476 |
| 1990-06-30 |
$471 |
| 1990-03-31 |
$471 |
| 1989-12-31 |
$430 |
| 1989-09-30 |
$432 |
| 1989-06-30 |
$430 |
| 1989-03-31 |
$416 |
| 1988-12-31 |
$419 |
| 1988-09-30 |
$423 |
| 1988-06-30 |
$272 |
| 1988-03-31 |
$237 |
| 1987-12-31 |
$238 |
| 1987-09-30 |
$253 |
| 1987-06-30 |
$260 |
| 1987-03-31 |
$222 |
| 1986-12-31 |
$217 |
| 1985-12-31 |
$121 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$201.199B |
$100.330B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
